Unexpectedly low immunocompetence in transplant patients on ketoconazole

Takuji Watanabe, Zu Hua Gao, Nozomi Shinozuka, Richard D. Schulick, Alexander Kuo, James F. Burdick

Research output: Contribution to journalArticle

Abstract

The P450 inhibitor ketoconazole may be used to decrease the dose, and therefore cost, of cyclosporine (CYA) by greatly decreasing the dose necessary to obtain therapeutic levels. However, the degree of immunosuppression produced using this drug regimen is not certain. We studied the immunocompetence of patients that had been started on ketoconazole to reduce the dose of CYA compared with patients treated conventionally. 95 assays were done in 64 patients including 6 assays in patients receiving low dose CYA plus ketoconazole. Immunocompetence was tested by measuring the mixed lymphocyte response using stimulators either non-depleted (ND) or depleted (D) of antigen presenting cells, based on the finding that CYA inhibits the response against D at a lower dose than against ND. Responses to ND/D ranged from +/+ through +/- to -/-. Normal individuals were always +/+. In conventionally treated patients with CYA the incidence of immunocompetence ≤ +/- was 48%, whereas all patients on CYA + ketoconazole had an immunocompetence score ≤ +/- (p = 0.03, χ2). This degree of immunosuppression contrasted strikingly with the chemical levels, which for those on ketoconazole were in the low acceptable area (182.3 ± 77.1 ng/ml range from 67 to 230 ng/ml), Therefore, patients using low-dose CYA plus ketoconazole to inhibit metabolism were more immunosuppressed than those receiving conventional CYA treatment, in spite of comparable CYA blood levels. If confirmed, this unexpectedly depressed immunocompetence in these patients would warrant caution in general regarding interpretation of trough blood levels in patients receiving CYA that are also being treated with agents that alter P450 activity.

Original languageEnglish (US)
Pages (from-to)599-603
Number of pages5
JournalClinical Transplantation
Volume11
Issue number6
StatePublished - Dec 1997

Fingerprint

Immunocompetence
Ketoconazole
Transplants
Immunosuppression
Antigen-Presenting Cells
Cyclosporine
Lymphocytes
Costs and Cost Analysis

Keywords

  • Cyclosporins
  • Immunocompetence
  • Ketoconazole
  • Kidney
  • Liver
  • Tacrolimus
  • Transplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Watanabe, T., Gao, Z. H., Shinozuka, N., Schulick, R. D., Kuo, A., & Burdick, J. F. (1997). Unexpectedly low immunocompetence in transplant patients on ketoconazole. Clinical Transplantation, 11(6), 599-603.

Unexpectedly low immunocompetence in transplant patients on ketoconazole. / Watanabe, Takuji; Gao, Zu Hua; Shinozuka, Nozomi; Schulick, Richard D.; Kuo, Alexander; Burdick, James F.

In: Clinical Transplantation, Vol. 11, No. 6, 12.1997, p. 599-603.

Research output: Contribution to journalArticle

Watanabe, T, Gao, ZH, Shinozuka, N, Schulick, RD, Kuo, A & Burdick, JF 1997, 'Unexpectedly low immunocompetence in transplant patients on ketoconazole', Clinical Transplantation, vol. 11, no. 6, pp. 599-603.
Watanabe T, Gao ZH, Shinozuka N, Schulick RD, Kuo A, Burdick JF. Unexpectedly low immunocompetence in transplant patients on ketoconazole. Clinical Transplantation. 1997 Dec;11(6):599-603.
Watanabe, Takuji ; Gao, Zu Hua ; Shinozuka, Nozomi ; Schulick, Richard D. ; Kuo, Alexander ; Burdick, James F. / Unexpectedly low immunocompetence in transplant patients on ketoconazole. In: Clinical Transplantation. 1997 ; Vol. 11, No. 6. pp. 599-603.
@article{f81f5df2719c4ea0a739867316c02058,
title = "Unexpectedly low immunocompetence in transplant patients on ketoconazole",
abstract = "The P450 inhibitor ketoconazole may be used to decrease the dose, and therefore cost, of cyclosporine (CYA) by greatly decreasing the dose necessary to obtain therapeutic levels. However, the degree of immunosuppression produced using this drug regimen is not certain. We studied the immunocompetence of patients that had been started on ketoconazole to reduce the dose of CYA compared with patients treated conventionally. 95 assays were done in 64 patients including 6 assays in patients receiving low dose CYA plus ketoconazole. Immunocompetence was tested by measuring the mixed lymphocyte response using stimulators either non-depleted (ND) or depleted (D) of antigen presenting cells, based on the finding that CYA inhibits the response against D at a lower dose than against ND. Responses to ND/D ranged from +/+ through +/- to -/-. Normal individuals were always +/+. In conventionally treated patients with CYA the incidence of immunocompetence ≤ +/- was 48{\%}, whereas all patients on CYA + ketoconazole had an immunocompetence score ≤ +/- (p = 0.03, χ2). This degree of immunosuppression contrasted strikingly with the chemical levels, which for those on ketoconazole were in the low acceptable area (182.3 ± 77.1 ng/ml range from 67 to 230 ng/ml), Therefore, patients using low-dose CYA plus ketoconazole to inhibit metabolism were more immunosuppressed than those receiving conventional CYA treatment, in spite of comparable CYA blood levels. If confirmed, this unexpectedly depressed immunocompetence in these patients would warrant caution in general regarding interpretation of trough blood levels in patients receiving CYA that are also being treated with agents that alter P450 activity.",
keywords = "Cyclosporins, Immunocompetence, Ketoconazole, Kidney, Liver, Tacrolimus, Transplantation",
author = "Takuji Watanabe and Gao, {Zu Hua} and Nozomi Shinozuka and Schulick, {Richard D.} and Alexander Kuo and Burdick, {James F.}",
year = "1997",
month = "12",
language = "English (US)",
volume = "11",
pages = "599--603",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Unexpectedly low immunocompetence in transplant patients on ketoconazole

AU - Watanabe, Takuji

AU - Gao, Zu Hua

AU - Shinozuka, Nozomi

AU - Schulick, Richard D.

AU - Kuo, Alexander

AU - Burdick, James F.

PY - 1997/12

Y1 - 1997/12

N2 - The P450 inhibitor ketoconazole may be used to decrease the dose, and therefore cost, of cyclosporine (CYA) by greatly decreasing the dose necessary to obtain therapeutic levels. However, the degree of immunosuppression produced using this drug regimen is not certain. We studied the immunocompetence of patients that had been started on ketoconazole to reduce the dose of CYA compared with patients treated conventionally. 95 assays were done in 64 patients including 6 assays in patients receiving low dose CYA plus ketoconazole. Immunocompetence was tested by measuring the mixed lymphocyte response using stimulators either non-depleted (ND) or depleted (D) of antigen presenting cells, based on the finding that CYA inhibits the response against D at a lower dose than against ND. Responses to ND/D ranged from +/+ through +/- to -/-. Normal individuals were always +/+. In conventionally treated patients with CYA the incidence of immunocompetence ≤ +/- was 48%, whereas all patients on CYA + ketoconazole had an immunocompetence score ≤ +/- (p = 0.03, χ2). This degree of immunosuppression contrasted strikingly with the chemical levels, which for those on ketoconazole were in the low acceptable area (182.3 ± 77.1 ng/ml range from 67 to 230 ng/ml), Therefore, patients using low-dose CYA plus ketoconazole to inhibit metabolism were more immunosuppressed than those receiving conventional CYA treatment, in spite of comparable CYA blood levels. If confirmed, this unexpectedly depressed immunocompetence in these patients would warrant caution in general regarding interpretation of trough blood levels in patients receiving CYA that are also being treated with agents that alter P450 activity.

AB - The P450 inhibitor ketoconazole may be used to decrease the dose, and therefore cost, of cyclosporine (CYA) by greatly decreasing the dose necessary to obtain therapeutic levels. However, the degree of immunosuppression produced using this drug regimen is not certain. We studied the immunocompetence of patients that had been started on ketoconazole to reduce the dose of CYA compared with patients treated conventionally. 95 assays were done in 64 patients including 6 assays in patients receiving low dose CYA plus ketoconazole. Immunocompetence was tested by measuring the mixed lymphocyte response using stimulators either non-depleted (ND) or depleted (D) of antigen presenting cells, based on the finding that CYA inhibits the response against D at a lower dose than against ND. Responses to ND/D ranged from +/+ through +/- to -/-. Normal individuals were always +/+. In conventionally treated patients with CYA the incidence of immunocompetence ≤ +/- was 48%, whereas all patients on CYA + ketoconazole had an immunocompetence score ≤ +/- (p = 0.03, χ2). This degree of immunosuppression contrasted strikingly with the chemical levels, which for those on ketoconazole were in the low acceptable area (182.3 ± 77.1 ng/ml range from 67 to 230 ng/ml), Therefore, patients using low-dose CYA plus ketoconazole to inhibit metabolism were more immunosuppressed than those receiving conventional CYA treatment, in spite of comparable CYA blood levels. If confirmed, this unexpectedly depressed immunocompetence in these patients would warrant caution in general regarding interpretation of trough blood levels in patients receiving CYA that are also being treated with agents that alter P450 activity.

KW - Cyclosporins

KW - Immunocompetence

KW - Ketoconazole

KW - Kidney

KW - Liver

KW - Tacrolimus

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0030656401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030656401&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 599

EP - 603

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 6

ER -